BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol 2010;14:29-44. [PMID: 19692274 DOI: 10.1016/j.ejpn.2009.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Mazunin IO, Volodko NV, Starikovskaya EB, Sukernik RI. Mitochondrial genome and human mitochondrial diseases. Mol Biol 2010;44:665-81. [DOI: 10.1134/s0026893310050018] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
2 Dean OM, Turner A, Malhi GS, Ng C, Cotton SM, Dodd S, Sarris J, Samuni Y, Tanious M, Dowling N, Waterdrinker A, Smith D, Berk M. Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Braz J Psychiatry 2015;37:3-12. [PMID: 25295681 DOI: 10.1590/1516-4446-2013-1341] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
3 Qintar M, Morad A, Alhawasli H, Shorbaji K, Firwana B, Essali A, Kadro W. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev 2012;:CD008523. [PMID: 22592731 DOI: 10.1002/14651858.CD008523.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
4 Finsterer J. Stroke and Stroke-like Episodes in Muscle Disease. Open Neurol J. 2012;6:26-36. [PMID: 22715346 DOI: 10.2174/1874205x01206010026] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
5 Giorgi C, Agnoletto C, Bononi A, Bonora M, De Marchi E, Marchi S, Missiroli S, Patergnani S, Poletti F, Rimessi A, Suski JM, Wieckowski MR, Pinton P. Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. Mitochondrion 2012;12:77-85. [PMID: 21798374 DOI: 10.1016/j.mito.2011.07.004] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 9.9] [Reference Citation Analysis]
6 Morén C, Hernández S, Guitart-Mampel M, Garrabou G. Mitochondrial toxicity in human pregnancy: an update on clinical and experimental approaches in the last 10 years. Int J Environ Res Public Health 2014;11:9897-918. [PMID: 25247430 DOI: 10.3390/ijerph110909897] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
7 Davis RE, Williams M. Mitochondrial function and dysfunction: an update. J Pharmacol Exp Ther 2012;342:598-607. [PMID: 22700430 DOI: 10.1124/jpet.112.192104] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
8 Darbandi S, Darbandi M, Khorshid HR, Sadeghi MR, Al-Hasani S, Agarwal A, Shirazi A, Heidari M, Akhondi MM. Experimental strategies towards increasing intracellular mitochondrial activity in oocytes: A systematic review. Mitochondrion 2016;30:8-17. [PMID: 27234976 DOI: 10.1016/j.mito.2016.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
9 Finsterer J. Treatment of central nervous system manifestations in mitochondrial disorders: Treatment of mitochondrial disorders. European Journal of Neurology 2011;18:28-38. [DOI: 10.1111/j.1468-1331.2010.03086.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
10 Frye RE, Rossignol D, Casanova MF, Brown GL, Martin V, Edelson S, Coben R, Lewine J, Slattery JC, Lau C, Hardy P, Fatemi SH, Folsom TD, Macfabe D, Adams JB. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health 2013;1:31. [PMID: 24350200 DOI: 10.3389/fpubh.2013.00031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
11 Montenegro L, Modica MN, Salerno L, Panico AM, Crascì L, Puglisi G, Romeo G. In Vitro Antioxidant Activity of Idebenone Derivative-Loaded Solid Lipid Nanoparticles. Molecules 2017;22:E887. [PMID: 28555014 DOI: 10.3390/molecules22060887] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
12 Scalais E, Francois B, Schlesser P, Stevens R, Nuttin C, Martin JJ, Van Coster R, Seneca S, Roels F, Van Goethem G, Löfgren A, De Meirleir L. Polymerase gamma deficiency (POLG): clinical course in a child with a two stage evolution from infantile myocerebrohepatopathy spectrum to an Alpers syndrome and neuropathological findings of Leigh's encephalopathy. Eur J Paediatr Neurol 2012;16:542-8. [PMID: 22342071 DOI: 10.1016/j.ejpn.2012.01.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
13 Yamada Y, Furukawa R, Yasuzaki Y, Harashima H. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol Ther 2011;19:1449-56. [PMID: 21694702 DOI: 10.1038/mt.2011.99] [Cited by in Crossref: 88] [Cited by in F6Publishing: 72] [Article Influence: 8.0] [Reference Citation Analysis]
14 Finsterer J, Bindu PS. Therapeutic strategies for mitochondrial disorders. Pediatr Neurol 2015;52:302-13. [PMID: 25701186 DOI: 10.1016/j.pediatrneurol.2014.06.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
15 Durhuus JA, Desler C, Rasmussen LJ. Mitochondria in Health and Disease – 3rd Annual Conference of Society for Mitochondrial Research and Medicine – 19–20 December 2013 — Bengaluru, India. Mitochondrion 2015;20:7-12. [DOI: 10.1016/j.mito.2014.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:135-45. [PMID: 23178231 DOI: 10.1016/j.pnpbp.2012.11.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 7.6] [Reference Citation Analysis]
17 Dunn DA, Cannon MV, Irwin MH, Pinkert CA. Animal models of human mitochondrial DNA mutations. Biochim Biophys Acta 2012;1820:601-7. [PMID: 21854831 DOI: 10.1016/j.bbagen.2011.08.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
18 Olszewska A, Szewczyk A. Mitochondria as a pharmacological target: magnum overview. IUBMB Life 2013;65:273-81. [PMID: 23441041 DOI: 10.1002/iub.1147] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
19 Pinho BR, Santos MM, Fonseca-Silva A, Valentão P, Andrade PB, Oliveira JM. How mitochondrial dysfunction affects zebrafish development and cardiovascular function: an in vivo model for testing mitochondria-targeted drugs. Br J Pharmacol 2013;169:1072-90. [PMID: 23758163 DOI: 10.1111/bph.12186] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
20 Al Shahrani M, Heales S, Hargreaves I, Orford M. Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson's Disease. J Clin Med 2017;6:E100. [PMID: 29077060 DOI: 10.3390/jcm6110100] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
21 Knerr I, Weinhold N, Vockley J, Gibson KM. Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects. J Inherit Metab Dis 2012;35:29-40. [PMID: 21290185 DOI: 10.1007/s10545-010-9269-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]